DEVELOPING A NURSE LED CLINIC TO DELIVER VORASIDINIB – PRACTICALITIES, PATIENTS AND OUTCOMES

Abstract AIMS The aim to establish a nurse-led service to facilitate patient access to Vorasidenib via the Managed Access Pro- gramme (MAP) independent of consultants’ clinic capacity; to define and pilot clinical management protocols; to quantify and evaluate the first cohort of patients treated. METHODS Patient eligibility was based on INDIGO study inclusion criteria. Clinicians and Clinical Nurse Specialists (CNSs) worked together to define protocols to deliver Vorasidinib within the Nurse Led setting. All patients were seen using a nurse led proforma signed off by the clinical team. RESULTS Between 1/6/24 and 1/2/25, 17 patients were referred from the Neuro-oncology MDT. 11/17 proceeded to treat- ment: 8 male/3 female. 6 patients did not commence treatment (4: patient choice, 2: deranged LFTs). Median age of patients treated: 41.1 years (21 – 65 years). 4/11 had 1 surgery; 4/11 2 surgeries, 3/11 3 surgeries. Median time from first surgery to commencing Vorasidenib was 40.7 months (range 5 – 93 months). Clinical protocol comprised: Months 1-2: fortnightly review, FBC/U&E/LFTs and ECG; Month 3 onwards: monthly review and FBC/U&E/LFTs. Response assessment: 6-monthly MR brain imaging. Total number of clinic appointments deliv- ered: 81. At 1/2/25, median number of cycles received was 4.1 (range 1-9). 4/11 patients had received 6 cycles and had re-assessment MR brain imaging; 4/4 showed stable disease. 10/11 patients reported no toxicity. 1/11 required treatment delay at cycle 2 followed by dose reduction due to raised LFTs (CTCAE V5.0 G3). Reponses to a patient satisfaction survey showed: 11/11 agreed (2/11, 18%) or strongly agreed (9/11, 82%) that they were happy with their experience of nurse led care. CONCLUSION Vorasidenib can be safely and efficiently delivered in a nurse led setting with low levels of toxicity and high levels of patient satisfaction.